Τίτλος:
Efficacy of the oral fluorouracil pro-drug capecitabine in cancer
treatment: a review
Γλώσσες Τεκμηρίου:
Αγγλικά
Περίληψη:
Capecitabine (Xeloda (R)) was developed as a pro-drug of fluorouracil
(FU), with the aim of improving tolerability and intratumor drug
concentrations through its tumor-specific conversion to the active drug.
The purpose of this paper is to review the available information on
capecitabine, focusing on its clinical effectiveness against various
carcinomas. Identification of all eligible English trails was made by
searching the PubMed and Cochrane databases from 1980 to 2007. Search
terms included capecitabine, Xeloda and cancer treatment. Nowadays, FDA
has approved the use of capecitabine as a first line therapy in patients
with metastatic colorectal cancer when single-agent fluoropyrimidine is
preferred. The drug is also approved for use as a single agent in
metastatic breast cancer patients who are resistant to both
anthracycline and paclitaxel-based regimens or when further
anthracycline treatment is contraindicated. It is also approved in
combination with docetaxel after failure of prior anthracycline-based
chemotherapy. In patients with prostate, pancreatic, renal cell and
ovarian carcinomas, capecitabine as a single-agent or in combination
with other drugs has also shown benefits. Improved tolerability and
comparable efficacy, compared with the intravenous FU/LV combination, in
addition to its oral administration, make capecitabine an attractive
option for the treatment of several types of carcinomas.
Συγγραφείς:
Koukourakis, Georgios V.
Kouloulias, Vassilios
Koukourakis,
Michael J.
Zacharias, Georgios A.
Zabatis, Haralabos and
Kouvaris, John
Περιοδικό:
Molecules (Basel, Switzerland)
Λέξεις-κλειδιά:
capecitabine; Xeloda; cancer treatment
DOI:
10.3390/molecules13081897
